Concepedia

Phase 2 Study of Lutetium 177–Labeled Anti–Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Marye J. Boers‐Sonderen, Tim J. van Oostenbrugge, Otto C. Boerman, Ingrid M.E. Desar, Alexander B. Stillebroer, Sasja F. Mulder, Carla M.L. van Herpen, Johan F. Langenhuijsen, Egbert Oosterwijk, Wim J.G. Oyen,

European Urology · 2015 · 104 citations · 8 references

DOI

Concepts

References

8

Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial

Chaitanya Divgi, Robert G. Uzzo, Constantine Gatsonis et al. · Journal of Clinical Oncology · 2012 · 258 citations · Full text

, , +17

Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma

Bradley C. Leibovich, Yuri Sheinin, Christine M. Lohse et al. · Journal of Clinical Oncology · 2007 · 197 citations

, , +17

Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma

Alexander B. Stillebroer, Otto C. Boerman, Ingrid M.E. Desar et al. · European Urology · 2012 · 97 citations

, , +12

Indium-111–labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma

Otto C. Boerman, Egbert Oosterwijk, J.F. Langenhuijsen et al. · European Urology · 2013 · 94 citations

, , +15

Dosimetric Analysis of <sup>177</sup>Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on <sup>111</sup>In-cG250 Imaging

Alexander B. Stillebroer, Catharina M.L. Zegers, Otto C. Boerman et al. · Journal of Nuclear Medicine · 2011 · 48 citations · Full text

, , +17